We are live on ! Find out more
IMGN

Immunogen Inc

Delisted

IMGN was delisted on the 9th of February, 2024.

131 hedge funds and large institutions have $423M invested in Immunogen Inc in 2014 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 50 increasing their positions, 37 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

179% more call options, than puts

Call options by funds: $11.2M | Put options by funds: $4.03M

35% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 37

7% less funds holding

Funds holding: 141131 (-10)

30% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 30

47% less capital invested

Capital invested by funds: $795M → $423M (-$372M)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
131
Holders Change
-10
Holders Change %
-7.09%
% of All Funds
3.49%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
21
Increased
50
Reduced
37
Closed
30
Calls
$11.2M
Puts
$4.03M
Net Calls
+$7.2M
Net Calls Change
+$2.39M
Name Holding Trade Value Shares
Change
Change in
Stake
Natixis Advisors
51
Natixis Advisors
Massachusetts
$562K +$48.6K +5,315 +6%
PIM
52
Platinum Investment Management
Australia
$552K
State Board of Administration of Florida Retirement System
53
State Board of Administration of Florida Retirement System
Florida
$546K
RhumbLine Advisers
54
RhumbLine Advisers
Massachusetts
$487K -$28.8K -3,145 -4%
ProShare Advisors
55
ProShare Advisors
Maryland
$460K -$27.6K -3,017 -4%
DADC
56
D.A. Davidson & Co
Montana
$456K +$138K +15,037 +25%
PPA
57
Parametric Portfolio Associates
Washington
$444K -$187K -20,405 -22%
BG
58
BlackRock Group
United Kingdom
$437K +$64K +7,000 +11%
MLICM
59
Metropolitan Life Insurance Company (MetLife)
New York
$423K
NFA
60
Nationwide Fund Advisors
Ohio
$401K -$323K -35,352 -35%
AIG
61
American International Group
New York
$376K -$22.3K -2,435 -4%
UBS Group
62
UBS Group
Switzerland
$341K +$511K +55,884 New
TC
63
TFS Capital
Pennsylvania
$336K -$140K -15,275 -22%
Prudential Financial
64
Prudential Financial
New Jersey
$330K +$401K +43,900 +429%
VOYA Investment Management
65
VOYA Investment Management
Georgia
$291K
BA
66
BlackRock Advisors
Delaware
$289K -$20.6K -2,248 -5%
DekaBank Deutsche Girozentrale
67
DekaBank Deutsche Girozentrale
Germany
$278K -$36.6K -4,000 -8%
NCCM
68
Nine Chapters Capital Management
New Jersey
$258K +$74.1K +8,100 +24%
LCM
69
Landscape Capital Management
New Jersey
$235K +$352K +38,500 New
PI
70
Placemark Investments
Illinois
$225K +$7.34K +803 +2%
Nomura Holdings
71
Nomura Holdings
Japan
$221K +$305K +33,301 New
BACM
72
Blue Arrow Capital Management
New York
$208K +$312K +34,095 New
T. Rowe Price Associates
73
T. Rowe Price Associates
Maryland
$204K +$29.4K +3,213 +11%
UBS AM
74
UBS AM
Illinois
$190K
Group One Trading
75
Group One Trading
Illinois
$188K -$174K -19,067 -38%

IMGN Hedge Fund Activity: Q4 2014 in Review

131 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Immunogen Inc (IMGN) for Q4 2014, worth a combined $423M — down 47% from $795M a quarter earlier.

Sellers outnumbered buyers: 30 funds closed out of IMGN and 21 opened new positions — a net loss of 9 holders — while 37 trimmed existing stakes and 50 added.

The largest buyer was Millennium Management, adding an estimated $12.3M. The largest seller was First Trust Advisors, exiting entirely with an estimated $61.5M sold.

  • 131 institutional investors held Immunogen Inc (IMGN) as of Q4 2014, down from 141 in Q3 2014.
  • Funds reported $423M of Immunogen Inc stock for Q4 2014, down 47% quarter-over-quarter.
  • 21 funds opened new Immunogen Inc positions in Q4 2014 and 30 closed out, a net change of -9 holders.
  • The largest Immunogen Inc buyer in Q4 2014 was Millennium Management, an estimated $12.3M added.
  • The largest Immunogen Inc seller in Q4 2014 was First Trust Advisors, an estimated $61.5M sold.

Based on aggregated 13F filings for Q4 2014.